Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_850
Snippet: Initial assessment of high dose dipyrone was well tolerated in horses when administered twice daily for 15 days. Neutrophils participate in innate immunity as the first line of host defense against microorganisms. However, exacerbated neutrophil activity can be harmful to surrounding tissues; this is important in a range of diseases, including allergic asthma and chronic obstructive pulmonary disease in humans, and equine asthma. Tamoxifen (TX) i.....
Document: Initial assessment of high dose dipyrone was well tolerated in horses when administered twice daily for 15 days. Neutrophils participate in innate immunity as the first line of host defense against microorganisms. However, exacerbated neutrophil activity can be harmful to surrounding tissues; this is important in a range of diseases, including allergic asthma and chronic obstructive pulmonary disease in humans, and equine asthma. Tamoxifen (TX) is a non-steroidal estrogen receptor modulator with effects on cell growth and survival. TX has been shown to induce early apoptosis of peripheral blood and bronchoalveolar lavage (BAL) neutrophils from horses with acute lung inflammation (Perez et al., 2016) . Our study group previously showed that neutrophil respiratory burst and IL-8-induced chemotaxis also decrease after treatment with TX, confirming a direct action of the drug on the cell type (Borlone et al., 2017) .
Search related documents:
Co phrase search for related documents- equine asthma and neutrophil activity: 1
- estrogen receptor and innate immunity: 1, 2
- lung inflammation and neutrophil activity: 1, 2, 3, 4
- lung inflammation and neutrophil show: 1
- lung inflammation and peripheral blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- lung inflammation and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- lung inflammation and study group: 1, 2, 3, 4, 5, 6, 7, 8, 9
- neutrophil activity and peripheral blood: 1, 2, 3, 4
- neutrophil activity and pulmonary disease: 1, 2
- neutrophil activity and study group: 1, 2
- neutrophil show and peripheral blood: 1
- neutrophil show and pulmonary disease: 1
- obstructive human pulmonary disease and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- peripheral blood and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- peripheral blood and study group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- pulmonary disease and study group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- pulmonary disease and TX treatment: 1
Co phrase search for related documents, hyperlinks ordered by date